36 results about "Speech disorder" patented technology

An individual that is speech impaired, such as a patient in a dentist's office, is provided with means to communicate with a service provider, such as a dentist, without the individual using their own voice. In one embodiment, a computing system initiates display of user interfaces on a display device that is visible to the speech impaired individual. The speech impaired individual may then select text phrases displayed on the display device using an input device, such as a wireless remote control. The communication systems selects one or more audio files that correspond with the selected text phrases and plays the audio file(s) so that the dentist hears the audible representation of the selected text phrase, such as via a headset that is worn by the dentist. In some embodiments, the patient is further able to select one or more educational and / or entertainment media items via the user interface.

A video calling system, method, and computer-readable medium for post-call redirection comprising the steps of initiating a video call between at least two call participants, wherein at least one of the call participants is deaf, hard-of-hearing, or speech impaired; enabling post-call redirection for the video call; determining when the video call ends; and, in response to determining that the first video call has ended, redirecting at least one of the call participants to a post-call destination

The invention discloses a system for lalopathy stress intervention on the basis of real-time rhythm multi-dimensional modeling. The system comprises a collecting device, a calculating device, a judging device and an intervention device, wherein the collecting device collects rhythm data; the calculating device obtains parameter values by calculating the rhythm data; the judging device enables the parameter values to be compared with a standard numerical range of the rhythm data, and if the parameter values are within the standard numerical range, lalopathy does not occur; if the parameter values are lower than or higher than the standard numerical range, the lalopathy occurs and a lalopathy type is judged; and the intervention device performs stress intervention according to the lalopathy type. The system has multi-dimensional characteristic parameters reflecting rhythm lalopathy, can reflect the characteristics of the rhythm lalopathy more comprehensively, enables assessment on lalopathy patients to be more accurate and enables rehabilitation training of the lalopathy patients to be more comprehensive and targeted. The invention further discloses a method for lalopathy stress intervention on the basis of real-time rhythm multi-dimensional modeling.

Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, incontinence, depresson, attention deficit disorder, attention deficit disorder with hyperactivity, bipolar and manic conditions, dysthymic disorder, and cyclothymic disorder, senile dementia, Alzheimer's type dementia, memory loss, amnesia / amnestic syndrome, disturbance of consciousness, coma, lowering of attention, speech disorders, Parkinson's disease, Lennox syndrome, autism, epilepsy, hyperkinetic syndrome and schizophrenia. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optionally pure sibutramine metabolites, wherein the sibutramine metabolite is selected from the group consisting of (+)-desmethylsibutramine, (-)-desmethylsibutramine, (±)-desmethylsibutramine, (+)-didesmethylsibutramine, (-)-didesmethylsibutramine, and (±)-didesmethylsibutramine.